A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

Inclusion Criteria

Concurrent Medication:

Allowed:

• Short-term nonsteroidal anti-inflammatory therapy.

Patients must have:

• HIV seropositivity.
• CD4 count >= 500 cells/mm3.
• Successful establishment of EBV-transformed B-cell lines at study entry.
• Consent of parent or guardian if < 18 years of age.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Suspected or known allergies to any vaccine components.
• Medical contraindication.
• Problem with compliance.

Concurrent Medication:

Excluded:

• Antiretroviral therapy (e.g., AZT, ddI, or ddC).
• Agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin).
• Parenteral therapies (including SC allergy sensitization).
• Other investigational HIV drugs or therapies.

Prior Medication:

Excluded:

• Any prior vaccinations against HIV.
• Antiretroviral therapy (e.g., AZT, ddI, or ddC) within the past 6 months.
• Agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin) within the past 3 months.
• Parenteral therapies (including SC allergy sensitization) within the past 3 months.
• Other investigational HIV drugs or therapies within the past 3 months.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety